B741 (CD80) as target for immunotoxin therapy for Hodgkin's disease
1997

Immunotoxin Therapy Targeting B7-1 for Hodgkin's Disease

publication Evidence: moderate

Author Information

Author(s): WC Vooijs, HG Otten, M van Vliet, AJG van Dijk, RA de Weger, M de Boer, H Bohlen, A Bolognesi, L Polito, GC de Gast

Primary Institution: University Hospital Utrecht

Hypothesis

Can an anti-B7-1 immunotoxin be an effective treatment for Hodgkin's disease?

Conclusion

The anti-B7-1 immunotoxin demonstrated strong cytotoxicity against Hodgkin's disease cell lines and may be a viable treatment option.

Supporting Evidence

  • Immunohistochemical analysis showed strong expression of B7-1 on Hodgkin and Reed-Sternberg cells.
  • Flow cytometric analysis indicated B7-1 was not expressed on resting T- or B-cells.
  • The anti-B7-1 immunotoxin exhibited strong cytotoxicity against B7-1 positive cell lines.
  • Clonogenic assays demonstrated a significant log kill of Hodgkin's disease cell lines.
  • No cytotoxicity was observed against B7-1 negative cell lines or hematopoietic progenitor cells.

Takeaway

Researchers created a special medicine that can kill cancer cells in Hodgkin's disease by targeting a specific protein on those cells.

Methodology

The study involved immunohistochemical analysis, flow cytometry, and cytotoxicity assays using various cell lines.

Limitations

The study is preclinical and results may not directly translate to human patients.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication